LILRP1: A Potential Drug Target Or Biomarker for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: LILRP1

NCBI ID: G79167

LILRP1

Other Name(s): Leukocyte immunoglobulin-like receptor pseudogene 1 | ILT9 | leukocyte immunoglobulin-like receptor pseudogene 1 | CD85l | LILRA6P

LILRP1: A Potential Drug Target Or Biomarker for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

LILRP1 (Leukocyte immunoglobulin-like receptor pseudogene 1) is a gene that encodes a protein known as LILRP1, which is a type of receptor found on the surface of certain immune cells. This protein plays a role in the immune response, specifically in the regulation of T cell development and function.

Recent studies have suggested that LILRP1 may be a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because LILRP1 has been shown to be involved in the regulation of immune cell function, and its dysfunction has been implicated in the development of these diseases.

One of the potential benefits of targeting LILRP1 is its potential to disrupt the immune response and promote the development of cancer. For example, LILRP1 has been shown to play a role in the regulation of T cell proliferation and differentiation, and alterations in T cell function have been implicated in the development of certain types of cancer. Additionally, LILRP1 has also been shown to promote the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Another potential mechanism by which LILRP1 may be involved in the development of autoimmune disorders is its role in the regulation of immune cell function. LILRP1 has been shown to play a role in the regulation of the immune response by promoting the activation and proliferation of immune cells. Additionally, LILRP1 has also been implicated in the regulation of the immune response by promoting the production of antibodies, which are proteins that are responsible for neutralizing foreign substances in the body.

In addition to its potential role in the development of cancer and autoimmune disorders, LILRP1 has also been suggested as a potential drug target for a variety of other conditions. For example, LILRP1 has been shown to play a role in the regulation of wound healing, and alterations in LILRP1 function have been implicated in the development of certain types of skin diseases. Additionally, LILRP1 has also been shown to play a role in the regulation of pain perception, and its dysfunction has been implicated in the development of certain types of pain disorders.

Overall, LILRP1 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Its role in the immune response and its potential involvement in the development of cancer, neurodegenerative diseases, and autoimmune disorders make it a promising target for future research and development. Further studies are needed to fully understand the role of LILRP1 in these processes and to develop safe and effective treatments.

Protein Name: Leukocyte Immunoglobulin-like Receptor Pseudogene 1

The "LILRP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LILRP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets